Abstract

Objective: Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is a primary cause of hospitalization and death in COPD. Serum CA-125 and red blood cell distribution width (RDW) are related to AECOPD. We investigated correlations between serum markers and AECOPD.

Methods: In total, 132 patients with AECOPD were included from January 2017 to December 2019. Participants were followed for 1 year. Patients were assigned to the poor prognosis (n = 40) or good prognosis (n = 92) group. We collected serum samples and general clinical information and conducted routine blood tests. We used logistic regression, receiver operating characteristic (ROC), and area under the ROC curve (AUC) analyses to assess differences between groups.

Results: We found significant differences between groups (odds ratio, 95% confidence interval) for age (1.046, 1.005–1.09), RDW (2.012, 1.339–3.023), and cancer antigen 125 (CA-125; 1.022, 1.006–1.039); these remained risk factors for AECOPD prognosis in multivariate analyses. RDW and CA-125 in combination was significant in ROC curve analysis. The AUC of RDW, CA-125, and these combined were 0.691, 0.779, and 0.772, respectively. Patients with RDW >12.75% and CA-125 >15.65 U/mL were predicted to have poor prognosis.

Conclusions: We found that RDW and CA-125 are potential prognostic indicators for AECOPD.
Introduction

Chronic obstructive pulmonary disease (COPD) is characterized by progressive, irreversible airflow limitation. COPD is one of the three main causes of death worldwide\textsuperscript{1,2} and an important public health challenge. Acute exacerbation of COPD (AECOPD) is a primary cause of hospitalization and is associated with high mortality.\textsuperscript{3,4} Hence, it is important to identify serological indicators that are readily available at the time of hospital admission to assess the prognosis of patients with AECOPD.

Red blood cell distribution width (RDW) is a clinical indicator of changes in red blood cell volume. A large number of studies have confirmed that an increase in RDW may lead to poor prognosis in cardiovascular diseases.\textsuperscript{5} RDW is also associated with the prognosis of COPD.\textsuperscript{6–8} The tumor marker cancer antigen 125 (CA-125) is mainly used in the diagnosis and screening of ovarian cancer. A few studies have indicated that serum CA-125 level is related to lung function in patients with COPD. However, few studies have investigated RDW combined with serum CA-125 level in the prognostic diagnosis of patients with AECOPD. In this study, we aimed to assess RDW value and CA-125 level as prognostic indicators of AECOPD. Our findings may provide a new method for the prognostic evaluation of patients with AECOPD.

Methods

We recruited inpatients who were diagnosed with AECOPD between January 2017 and December 2019. The inclusion criteria for AECOPD were in accordance with the 2007 revised Guidelines for the Diagnosis and Treatment of Chronic Obstructive Pulmonary Diseases in China. Patients complicated with primary heart valvular disease, arthritis, connective tissue disease, inflammatory bowel disease, renal failure, liver and blood system diseases or suspected malignancy were excluded from the analysis. Patients were followed up for treatment effect or death over a period of 1 year. Patients who died and those readmitted to the hospital within 90 days after discharge were assigned to the poor-prognosis group; the remaining patients were assigned to the good-prognosis group. Patients were assessed in subgroups of 10-year intervals.

Serum samples were collected within 24 hours of admission. We collected general clinical information and routine blood test results. The following parameters were examined: sex, age, smoking history, length of hospital stay, white blood cells, C-reactive protein, neutrophil absolute value, RDW, type B natriuretic peptide (BNP), CA-125, albumin, uric acid, and gamma-glutamyl transferase.

This study protocol was approved by the Beijing Chaoyang District Shuangqiao Hospital ethics review committee.
The patients in this study provided their verbal informed consent.

**Statistical analysis**

IBM SPSS 25.0 software was used for data analysis (IBM Corp., Armonk, NY, USA). Measurement data conforming to a normal distribution are expressed as mean ± standard deviation. We used an independent samples *t*-test and Wilcoxon rank-sum test for comparisons between the groups. Measurement data with a non-normal distribution are expressed using median (25th percentile, 75th percentile). Enumeration data are expressed as n (%), and comparisons between groups was performed using the χ² test. Logistic regression analysis was used in multivariate analysis. The diagnostic ability of each index was analyzed in receiver operating characteristic (ROC) curve analysis. *P* < 0.05 indicated statistical significance.

**Results**

A total of 132 (86 men, 46 women) were included in this study. Patient ages ranged from 55 to 103 years old. Forty patients were assigned to the poor-prognosis group, and 92 patients were assigned to the good-prognosis group, with a significant difference in age (*P* < 0.05) between groups (Table 1).

In a comparison of serologic markers between the two groups, we found significant differences in RDW, BNP, and CA-125 (*P* < 0.05) (Table 2).

Single-factor logistic regression analysis was conducted for all indicators. We found significant differences for age (odds ratio [OR] 1.046, 95% confidence interval [CI] 1.005 to 1.09), RDW (OR 2.012, 95% CI 1.339 to 3.023), and CA-125 (OR 1.022, 95% CI 1.006–1.039) between the two groups (all *P* < 0.05). These indicators were included in multifactor logistic regression analysis; RDW (*P* = 0.004) and CA-125 (*P* = 0.040) remained statistically significant. Thus, age, RDW, and CA-125 were independent risk factors for prognosis. Higher values of age, RDW, and CA-125 were associated with greater likelihood of a poor prognosis (Table 3).

Combined diagnostic indicators were included in the multivariate logistic regression function. RDW, CA-125, and these two indicators combined were statistically significant in ROC curve analysis of prognosis (*P* < 0.05). The area under the ROC curve for RDW, CA-125, and for these

| Table 1. Comparison of clinical data between the two groups. |
|-------------------------------------------------------------|
| **Good prognosis** | **Poor prognosis** | χ² | *P*-value |
| **Sex** | | | |
| Female | 32 (34.8) | 14 (35.0) | 0.001 | 0.981 |
| Male | 60 (65.2) | 26 (65.0) | | |
| **Smoking** | | | | |
| No | 30 (32.6) | 12 (30.0) | 0.087 | 0.767 |
| Yes | 62 (67.4) | 28 (70.0) | | |
| **Length of hospital stay** | | | | |
| 11.77 ± 4.42 | 11.78 ± 6.09 | 0.003 | 0.997 |
| **Age** | | | | |
| 73.22 ± 9.57 | 77.35 ± 9.95 | 2.253 | 0.026 |
| **Age group, years** | | | | |
| ≤60 | 7 (7.6) | 7 (17.5) | 9.566 | 0.023 |
| ≤70 | 16 (17.4) | 14 (35) | | |
| ≤80 | 38 (41.3) | 10 (25) | | |
| >80 | 31 (33.7) | 9 (22.5) | | |

Note: Values in the table are n (%), unless otherwise indicated.
Table 2. Comparison of serologic markers between the two groups.

|                   | Good prognosis | Poor prognosis | $\chi^2$ or $t$ or $Z$ | $P$-value |
|-------------------|----------------|----------------|------------------------|-----------|
| WBC ($10^9$ cells/L) | 8.80 ± 3.82    | 8.61 ± 3.58    | 0.279$^a$              | 0.781     |
| CRP (mg/L)        | 28.00 (8.25, 98.5) | 39.50 (9.25, 102.75) | −0.473$^b$           | 0.636     |
| Neutrophils ($10^9$ cells/L) | 6.58 ± 3.48 | 6.84 ± 3.75 | −0.379$^a$             | 0.705     |
| RDW (%)           | 12.75 ± 0.86   | 13.56 ± 1.40   | 3.383$^a$              | 0.001     |
| BNP (pg/mL)       | 73 (34.75, 173.25) | 123.50 (79.75, 237.00) | −2.595$^b$         | 0.009     |
| CA-125 (U/mL)     | 10.75 (7.20, 16.33) | 19.95 (15.88, 39.75) | −5.085$^b$           | <0.001    |
| ALB (g/L)         | 37.81 ± 5.20   | 36.38 ± 7.32   | 1.271$^a$              | 0.206     |
| UA (μmol/L)       | 262.08 ± 104.16 | 280.43 ± 105.68 | −0.926$^a$            | 0.356     |
| GGT (U/L)         | 23 (14, 40.75)  | 21 (14, 40.5)   | −0.352$^b$            | 0.725     |
| Creatinine (μmol/L) | 62.5 (53, 77)  | 63.5 (55.25, 76.75) | −0.911$^b$          | 0.362     |
| Urea nitrogen (mmol/L) | 5.23 (3.98, 6.87) | 4.68 (3.99, 6.93) | −0.594$^b$           | 0.552     |
| ALT (U/L)         | 13 (11, 20)    | 16.5 (12, 23.50) | −1.535$^b$           | 0.125     |
| AST (U/L)         | 18.5 (15, 24)  | 20.5 (16, 27.75) | −1.084$^b$           | 0.279     |

$^a$Independent samples $t$-test. $^b$Wilcoxon rank-sum test.
Values in the table are mean ± standard deviation or median (25th percentile, 75th percentile).
WBC, white blood cells; CRP, C-reactive protein; RDW, red blood cell distribution width; BNP, type B natriuretic peptide; CA-125, cancer antigen 125; ALB, albumin; UA, uric acid; GGT, gamma-glutamyl transferase; ALT, alanine aminotransferase, AST, aspartate aminotransferase.

Table 3. Logistic regression analysis for prognostic ability.

|                | Single factor logistic regression analysis | Multivariate logistic regression analysis |
|----------------|-------------------------------------------|------------------------------------------|
|                | OR (95% CI) | $P$ | OR (95% CI) | $P$-value |
| Sex            | 1.010 (0.462, 2.199) | 0.981 | 1.048 (1.002, 1.096) | 0.040 |
| Smoking        | 1.129 (0.505, 2.524) | 0.768 |                        |        |
| Length of hospital stay | 1.000 (0.928, 1.078) | 0.997 |                        |        |
| Age            | 1.046 (1.005, 1.090) | 0.029 | 1.046 (1.005, 1.090) | 0.029 |
| WBC            | 0.986 (0.891, 1.090) | 0.779 | 1.002 (0.997, 1.007) | 0.489 |
| CRP            | 1.002 (0.997, 1.007) | 0.489 | 1.002 (0.997, 1.007) | 0.489 |
| Neutrophils    | 1.020 (0.920, 1.131) | 0.703 | 1.020 (0.920, 1.131) | 0.703 |
| RDW            | 2.012 (1.339, 3.023) | 0.001 | 2.012 (1.339, 3.023) | 0.001 |
| BNP            | 1.001 (1.000, 1.002) | 0.216 | 1.001 (1.000, 1.002) | 0.216 |
| CA-125         | 1.022 (1.006, 1.039) | 0.006 | 1.022 (1.006, 1.039) | 0.006 |
| ALB            | 0.958 (0.897, 1.024) | 0.207 | 0.958 (0.897, 1.024) | 0.207 |
| UA             | 1.002 (0.998, 1.005) | 0.354 | 1.002 (0.998, 1.005) | 0.354 |
| GGT            | 1.000 (0.990, 1.012) | 0.930 | 1.000 (0.990, 1.012) | 0.930 |
| Creatinine     | 1.001 (0.989, 1.014) | 0.841 | 1.001 (0.989, 1.014) | 0.841 |
| Urea nitrogen  | 0.995 (0.853, 1.159) | 0.946 | 0.995 (0.853, 1.159) | 0.946 |
| ALT            | 1.013 (0.995, 1.032) | 0.158 | 1.013 (0.995, 1.032) | 0.158 |
| AST            | 1.010 (0.991, 1.030) | 0.307 | 1.010 (0.991, 1.030) | 0.307 |

OR, odds ratio; CI, confidence interval; WBC, white blood cells; CRP, C-reactive protein; RDW, red blood cell distribution width; BNP, type B natriuretic peptide; CA-125, cancer antigen 125; ALB, albumin; UA, uric acid; GGT, gamma-glutamyl transferase; ALT, alanine aminotransferase, AST, aspartate aminotransferase.
indicators combined was 0.691, 0.779, and 0.772, respectively. The cutoff values for RDW and CA-125 were 12.75 and 15.65. The prognostic ability of CA-125, and of RDW and CA-125 combined, was close to but superior to that of RDW alone (Table 4, Figure 1).

**Discussion**

COPD is a common respiratory disease, especially in older people, with high morbidity and mortality. Timely and accurate assessment of the severity of disease and appropriate treatment measures are important to improve patient prognosis.

In this study, we found that age was a risk factor for prognosis in patients with AECOPD, as reported in other studies. Older patients with AECOPD have poorer outcomes, which can be explained by a natural decline in lung function. Additionally, older patients often have multiple comorbidities, making them more vulnerable to exacerbation, which contributes to a poor AECOPD prognosis.

RDW is a routine blood test that can quantitatively reflect the volume difference

| Table 4. ROC curve analysis of prognostic ability for each index. |
| --- | --- | --- | --- | --- | --- |
| | AUC (95% Cl) | SE | P | Boundary value | Sensibility | Specificity | Youden index |
| RDW | 0.691 (0.595, 0.788) | 0.049 | <0.001 | 12.750 | 0.775 | 0.533 | 0.308 |
| CA-125 | 0.779 (0.696, 0.862) | 0.042 | <0.001 | 15.650 | 0.775 | 0.750 | 0.525 |
| Combined diagnostic indicator | 0.772 (0.690, 0.855) | 0.042 | <0.001 | —— | 0.800 | 0.674 | 0.474 |

ROC, receiver operating characteristic; AUC, area under the ROC curve; SE, standard error; RDW, red blood cell distribution width; CA-125, cancer antigen 125.

**Figure 1.** Receiver operating characteristic curve of red blood cell distribution width, cancer antigen 125, and the combined diagnostic indicator for prognosis.
in peripheral blood red cells. Infection, anemia, nutritional deficiency, and other factors can lead to an increase in RDW. Several recent studies have confirmed the independent correlation between RDW and cardiovascular disease. Similar mechanisms and relationships between COPD and cardiovascular disease have been identified related to inflammation, oxidative stress, and endothelial dysfunction. Inflammatory cytokines also lead to increased RDW by inhibiting erythropoietin-induced erythrocyte maturation. Additionally, high RDW reflects an underlying chronic inflammatory response in the body. Inflammatory response is an important pathogenesis in COPD, which is closely related to disease severity and patient prognosis. AECOPD can enhance the systemic inflammatory response and promote the release of inflammatory cells and inflammatory mediators. In this study, our analysis showed that RDW was an independent risk factor for AECOPD. RDW is significantly associated with prognosis in patients with AECOPD, with higher RDW associated with worse prognosis. This may be owing to the combined effects of high oxidative stress, severe inflammatory response, and activation of the neuroendocrine system.

Serum CA-125 measurement is convenient and inexpensive in clinical practice. Serum CA-125 level is often used in the clinic for the diagnosis and differential diagnosis of ovarian tumors. It has also been reported that serum CA-125 is elevated in other diseases. In the respiratory system, CA-125 is mainly distributed in submucosal cells and goblet epithelial cells. Levels of CA-125 have been shown to be independently influenced by the right heart chambers. It has been reported that CA-125 can be used in the differential diagnosis of heart failure. Another study showed that CA-125 is associated with severity and fluid retention in chronic heart failure. CA-125 is associated with an enlarged right ventricular lumen in right ventricular dysfunction. These findings suggest that increased cardiac pressure may be a mechanism for the upregulated expression of serum CA-125. Uz et al. reported a correlation between CA-125 and pulmonary artery systolic pressure. Some clinical studies have shown that patients with COPD often have different degrees of cardiovascular injury. Several previous studies have reported that CA-125 is associated with prognosis in patients with COPD. Similarly, in this study, serum CA-125 was an independent risk factor for AECOPD and had good diagnostic ability in the prognosis of AECOPD.

To further confirm the relationship between RDW, CA-125, and AECOPD prognosis, we used a combined diagnostic indicator, based on the results of multiple logistic regression analysis. RDW, CA-125, and the combination of these two indicators were statistically significant in ROC curve analysis of prognosis ($P < 0.05$). According to cutoff values, patients with RDW greater than 12.75% and CA-125 greater than 15.65 U/mL were predicted to have poor prognosis. We suggest that RDW and CA-125 can be used as prognostic indicators for AECOPD.

There are some limitations of this study. This was a single-center, retrospective study, and some data were missing, such as outpatient medications. Additionally, we underestimated the number of readmissions as we did not include admissions from other hospitals.

**Conclusion**

In this study, we found that the RDW value and serum CA-125 level are potential prognostic indicators for AECOPD. These findings can provide a reference for clinicians.

**Declaration of conflicting interest**

The authors declare that there is no conflict of interest.
**Funding**

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

**ORCID iDs**

Fang He  
https://orcid.org/0000-0002-1712-2309  
Ping Zhao  
https://orcid.org/0000-0003-3646-6673

**References**

1. Global Health Metrics. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018; 392: 1736–1788.
2. Mathers CD and Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. *PLoS Med* 2006; 3: e442.
3. Lima FV, Yen TY and Patel JK. Trends in in-hospital outcomes among adults hospitalized with exacerbation of chronic obstructive pulmonary disease. *COPD* 2015; 12: 636–642.
4. Singanayagam A, Schembri S and Chalmers JD. Predictors of mortality in hospitalized adults with acute exacerbation of chronic obstructive pulmonary disease. *Ann Am Thorac Soc* 2013; 10: 81–89.
5. De Amicis MM, Chivite D, Corbella X, et al. Anemia is a mortality prognostic factor in patients initially hospitalized for acute heart failure. *Intern Emerg Med* 2017; 12: 749–756.
6. Tertemiz KC, Ozgen Alpaydin A, Sevinc C, et al. Could “red cell distribution width” predict COPD severity? *Rev Port Pneumol (2006)* 2016, 22: 196–201.
7. Balta S, Aydogan M, Demirkol S, et al. Red cell distribution width: a novel and simple predictor of mortality in chronic obstructive pulmonary disease. *COPD* 2014; 11: 475–476.
8. Karampitsakos T, Dimakou K, Papaioannou O, et al. The role of increased red cell distribution width as a negative prognostic marker in patients with COPD. *Pulm Pharmacol Ther* 2020; 60: 101877.
9. Benfield T, Lange P, Vestbo J. COPD stage and risk of hospitalization for infectious disease. *Chest* 2008; 134: 46–53.
10. Groenewegen KH, Schols AM and Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. *Chest* 2003; 124: 459–467.
11. Patil SP, Krishnan JA, Lechtzin N, et al. In-hospital mortality following acute exacerbations of chronic obstructive pulmonary disease. *Arch Intern Med* 2003; 163: 1180–1186.
12. Roche N, Zureik M, Soussan D, et al. Predictors of outcomes in COPD exacerbation cases presenting to the emergency department. *Eur Respir J* 2008; 32: 953–961.
13. Burrows B, Bloom JW, Traver GA, et al. The course and prognosis of different forms of chronic airways obstruction in a sample from the general population. *N Engl J Med* 1987; 317: 1309–1314.
14. Lippi G and Plebani M. Red blood cell distribution width (RDW) and human pathology. *Clin Chem Lab Med* 2014; 52: 1247–1249.
15. Tonelli M, Sacks F, Amold M, et al. Relation between red blood cell distribution width and cardiovascular event rate in people with coronary disease. *Circulation* 2008; 117: 163–168.
16. Moy ML, Teylan M, Danilack VA, et al. An index of daily step count and systemic inflammation predicts clinical outcomes in chronic obstructive pulmonary disease. *Ann Am Thorac Soc* 2014; 11: 149–157.
17. Varol E, Ozaydin M, Altinbas A, et al. Elevated carbohydrate antigen 125 levels in hypertrophic cardiomyopathy patients with heart failure. *Heart Vessels* 2007; 22: 30–33.
18. Sjövall K, Nilsson B and Einhorn N. The significance of serum CA 125 elevation in malignant and nonmalignant diseases. *Gynecol Oncol* 2002; 85: 175–178.
19. Reisfiker M and Yilmaz MB. Association of right heart with CA-125 levels in patients with heart failure. *Int J Cardiol*. In press.
20. Zhuang J, Faggiano P, Li Q, et al. Insights into the clinical implications of carbohydrate antigen 125 as a biomarker of heart failure: a
meta-analysis and systematic review of published studies. *J Cardiovasc Med* 2014; 15: 864–872.

21. Kouris NT, Zacharos ID, Kontogianni DD, et al. The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters. *Eur J Heart Fail* 2005, 7: 199–203.

22. Uz O, Kardesoglu E, Tas D, et al. CA-125 level is associated with right ventricular echocardiographic parameters in patients with COPD. *South Med J* 2011; 104: 624–628.

23. Rodríguez-Pascual C, Paredes-Galán E, Ferrero-Martínez AI, et al. The frailty syndrome is associated with adverse health outcomes in very old patients with stable heart failure: a prospective study in six Spanish hospitals. *Int J Cardiol* 2017; 236: 296–303.

24. Zhang M, Li YL, Yang X, et al. Clinical significance of serum carbohydrate antigen 125 in acute exacerbation of chronic obstructive pulmonary disease. *Nan Fang Yi Ke Da Xue Xue Bao* 2016; 36: 1386–1389 [in Chinese].

25. Kaya H, Zorlu A, Yucel H, et al. Cancer antigen-125 levels predict long-term mortality in chronic obstructive pulmonary disease. *Biomarkers* 2015; 20: 162–167.